Mesenchymal stem cell-derived exosomes facilitate nasopharyngeal carcinoma progression

American Journal of Cancer Research

Volumn 6, Issue 2, 2016, Pages 459-472

  Shi, Si ^a   Zhang, Qicheng ^a   Xia, Yunfei ^a   You, Bo ^a   Shan, Ying ^a   Bao, Lili ^a   Li, Li ^a   You, Yiwen ^a   Gu, Zhifeng ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Epithelialmesenchymal transition (EMT); Exosomes; FGF19 FGFR4 signaling; Mesenchymal stem cells (MSCs); Metastasis; Nasopharyngeal carcinoma (NPC)

Indexed keywords

FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR RECEPTOR 4; MITOGEN ACTIVATED PROTEIN KINASE; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOMA CELL; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSPORT; CELL VACUOLE; CELLULAR SECRETION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; EXOSOME; FEMALE; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MOLECULAR MECHANICS; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT DURATION;

EID: 84981762948     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
2. Robinson BD, Sica GL, Liu YF, Rohan TE, Gertler FB, Condeelis JS and Jones JG. Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination. Clin Cancer Res 2009; 15: 2433-2441.
3. Salem HK and Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 2010; 28: 585-596.
4. Droujinine IA, Eckert MA and Zhao W. To grab the stroma by the horns: from biology to cancer therapy with mesenchymal stem cells. Oncotarget 2013; 4: 651-664.
5. Kidd S, Spaeth E, Dembinski JL, Dietrich M, Watson K, Klopp A, Battula VL, Weil M, Andreeff M and Marini FC. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 2009; 27: 2614-2623.
6. Klopp AH, Gupta A, Spaeth E, Andreeff M and Marini F 3rd. Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells 2011; 29: 11-19.
7. Jordan NV, Johnson GL and Abell AN. Tracking the intermediate stages of epithelial-mesenchymal transition in epithelial stem cells and cancer. Cell Cycle 2011; 10: 2865-2873.
8. Martin FT, Dwyer RM, Kelly J, Khan S, Murphy JM, Curran C, Miller N, Hennessy E, Dockery P, Barry FP, O'Brien T and Kerin MJ. Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res Treat 2010; 124: 317-326.
9. Vlassov AV, Magdaleno S, Setterquist R and Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta 2012; 1820: 940-948.
10. Buhmeida A, Dallol A, Merdad A, Al-Maghrabi J, Gari MA, Abu-Elmagd MM, Chaudhary AG, Abuzenadah AM, Nedjadi T, Ermiah E, Al-Thubaity F and Al-Qahtani MH. High fibroblast growth factor 19 (FGF19) expression predicts worse prognosis in invasive ductal carcinoma of breast. Tumour Biol 2014; 35: 2817-2824.
11. Yu B, Zhang X and Li X. Exosomes derived from mesenchymal stem cells. Int J Mol Sci 2014; 15: 4142-4157.
12. Du T, Ju G, Wu S, Cheng Z, Cheng J, Zou X, Zhang G, Miao S, Liu G and Zhu Y. Microvesicles derived from human Wharton's jelly mesenchymal stem cells promote human renal cancer cell growth and aggressiveness through induction of hepatocyte growth factor. PLoS One 2014; 9: e96836.
13. Ornitz DM and Itoh N. Fibroblast growth factors. Genome Biol 2001; 2: REVIEWS3005.
14. Lin BC and Desnoyers LR. FGF19 and cancer. Adv Exp Med Biol 2012; 728: 183-194.
15. Harmer NJ, Pellegrini L, Chirgadze D, Fernandez-Recio J and Blundell TL. The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity. Biochemistry 2004; 43: 629-640.
16. Fu L, John LM, Adams SH, Yu XX, Tomlinson E, Renz M, Williams PM, Soriano R, Corpuz R, Moffat B, Vandlen R, Simmons L, Foster J, Stephan JP, Tsai SP and Stewart TA. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004; 145: 2594-2603.
17. Feng S, Dakhova O, Creighton CJ and Ittmann M. Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res 2013; 73: 2551-2562.
18. Miura S, Mitsuhashi N, Shimizu H, Kimura F, Yoshidome H, Otsuka M, Kato A, Shida T, Okamura D and Miyazaki M. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer 2012; 12: 56.
19. Gu Z, Cao X, Jiang J, Li L, Da Z, Liu H and Cheng C. Upregulation of p16INK4A promotes cellular senescence of bone marrow-derived mesenchymal stem cells from systemic lupus erythematosus patients. Cell Signal 2012; 24: 2307-2314.
20. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA, Hopmans ES, Lindenberg JL, de Gruijl TD, Wurdinger T and Middeldorp JM. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci U S A 2010; 107: 6328-6333.
21. You Y, Yao H, You B, Li X, Ni H, Shi S, Shan Y and Cao X. Clinical significance of HAX-1 expression in laryngeal carcinoma. Auris Nasus Larynx 2015; 42: 299-304.
22. Thiery JP and Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7: 131-142.
23. Desnoyers LR, Pai R, Ferrando RE, Hotzel K, Le T, Ross J, Carano R, D'Souza A, Qing J, Mohtashemi I, Ashkenazi A and French DM. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008; 27: 85-97.
24. Pai R, Dunlap D, Qing J, Mohtashemi I, Hotzel K and French DM. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling. Cancer Res 2008; 68: 5086-5095.
25. Kidd S, Spaeth E, Watson K, Burks J, Lu H, Klopp A, Andreeff M and Marini FC. Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS One 2012; 7: e30563.
26. Quante M, Tu SP, Tomita H, Gonda T, Wang SS, Takashi S, Baik GH, Shibata W, Diprete B, Betz KS, Friedman R, Varro A, Tycko B and Wang TC. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011; 19: 257-272.
27. De Boeck A, Pauwels P, Hensen K, Rummens JL, Westbroek W, Hendrix A, Maynard D, Denys H, Lambein K, Braems G, Gespach C, Bracke M and De Wever O. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling. Gut 2013; 62: 550-560.
28. Wang ML, Pan CM, Chiou SH, Chen WH, Chang HY, Lee OK, Hsu HS and Wu CW. Oncostatin m modulates the mesenchymal-epithelial transition of lung adenocarcinoma cells by a mesenchymal stem cell-mediated paracrine effect. Cancer Res 2012; 72: 6051-6064.
29. Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Kodama M, Higashi Y, Tanaka S, Yasui W and Chayama K. Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer 2010; 127: 2323-2333.
30. Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell 2012; 10: 709-716.
31. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R and Weinberg RA. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449: 557-563.
32. Thery C, Ostrowski M and Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009; 9: 581-593.
33. Zoller M. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer 2009; 9: 40-55.
34. Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, Azab F, Flores LM, Campigotto F, Weller E, Anderson KC, Scadden DT and Ghobrial IM. BM mesenchymal stromal cellderived exosomes facilitate multiple myeloma progression. J Clin Invest 2013; 123: 1542-1555.
35. Bruno S, Collino F, Deregibus MC, Grange C, Tetta C and Camussi G. Microvesicles derived from human bone marrow mesenchymal stem cells inhibit tumor growth. Stem Cells Dev 2013; 22: 758-771.
36. Polyak K and Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-273.
37. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M and Nieto MA. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 2009; 119: 1438-1449.
38. Zhu W, Huang L, Li Y, Qian H, Shan X, Yan Y, Mao F, Wu X and Xu WR. Mesenchymal stem cell-secreted soluble signaling molecules potentiate tumor growth. Cell Cycle 2011; 10: 3198-3207.
39. Zhu W, Huang L, Li Y, Zhang X, Gu J, Yan Y, Xu X, Wang M, Qian H and Xu W. Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo. Cancer Lett 2012; 315: 28-37.
40. Goetz R, Beenken A, Ibrahimi OA, Kalinina J, Olsen SK, Eliseenkova AV, Xu C, Neubert TA, Zhang F, Linhardt RJ, Yu X, White KE, Inagaki T, Kliewer SA, Yamamoto M, Kurosu H, Ogawa Y, Kuro-o M, Lanske B, Razzaque MS and Mohammadi M. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 2007; 27: 3417-3428.
41. Liu R, Li J, Xie K, Zhang T, Lei Y, Chen Y, Zhang L, Huang K, Wang K, Wu H, Wu M, Nice EC, Huang C and Wei Y. FGFR4 promotes stromainduced epithelial-to-mesenchymal transition in colorectal cancer. Cancer Res 2013; 73: 5926-5935.
42. Roidl A, Berger HJ, Kumar S, Bange J, Knyazev P and Ullrich A. Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin Cancer Res 2009; 15: 2058-2066.